A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation.

ABSTRACT: Biologic agents have revolutionized the management of serious health conditions in the last two decades. The use of "targeted therapy" brings not only better progression free survivals and overall survivals, but also better toxicity profiles and quality of life benefits, compared to empirical palliative chemotherapy. However, given the high cost associated with biologic drugs and the sharp increases in biologic drug utilization, this drug category has significantly raised healthcare cost over the years. A similar phenomenon was previously experienced with branded simple chemical compound drugs, including chemotherapeutic agents, which was largely mitigated by the introduction of a generic approval pathway, decreasing the costs of the drugs, making them more affordable, given to the increas

SUBMITTER: Garcia JJ 

PROVIDER: S-EPMC7653109 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature